A novel approach to contrast-enhanced breast magnetic resonance imaging for screening: High-resolution ultrafast dynamic imaging

Investigative Radiology

Volumn 49, Issue 9, 2014, Pages 579-585

  Mann, Ritse M ^a   Mus, Roel D ^a   Van Zelst, Jan ^a   Geppert, Christian ^b   Karssemeijer, Nico ^c   Platel, Bram ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SIEMENS CORPORATE RESEARCH   (United States)

^c FRAUNHOFER MEVIS   (Germany)

Author keywords

breast cancer; contrast enhancement versus time curve; costs; dynamic contrast enhanced (DCE) breast MRI; MRI protocol length reduction; screening; ultrafast dynamic MRI

Indexed keywords

GADOTERATE MEGLUMINE; CONTRAST MEDIUM;

ANGIOGRAPHY; ARTICLE; BREAST CANCER; CANCER SCREENING; CONTRAST ENHANCEMENT; COST; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMAGING SYSTEM; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; BREAST NEOPLASMS; COMPARATIVE STUDY; EVALUATION STUDY; FEMALE; PROCEDURES; RETROSPECTIVE STUDY;

BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDIES;

EID: 84905862327     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0000000000000057     Document Type: Article

References (58)

1. Kuhl CK, Schrading S, Bieling HB, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet. 2007;370: 485-492. (Pubitemid 47214635)
2. Peters NH, Borel Rinkes I, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology. 2008;246:116-124. (Pubitemid 350305034)
3. Carbonaro LA, Pediconi F, Verardi N, et al. Breast MRI using a high-relaxivity contrast agent: an overview. AJR Am J Roentgenol. 2011;196:942-955.
4. Kuhl CK. Breast MR imaging at 3 T. Magn Reson Imaging Clin North Am. 2007;15:315-320, vi.
5. Pinker-Domenig K, Bogner W, Gruber S, et al. High resolution MRI of the breast at 3 T: which BI-RADS(R) descriptors are most strongly associated with the diagnosis of breast cancer? Eur Radiol. 2012;22:322-330.
6. Boetes C, Mann RM. Ductal carcinoma in situ and breast MRI. Lancet. 2007;370:459-460. (Pubitemid 47212352)
7. Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, et al. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging. J Natl Cancer Inst. 2013;105:1314-1321.
8. Pataky R, Armstrong L, Chia S, et al. Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. BMC Cancer. 2013;13:339.
9. Griebsch I, Brown J, Boggis C, et al. Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer. 2006;95:801-810. (Pubitemid 44498093)
10. Mann RM, Kuhl CK, Kinkel K, et al. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008;18:1307-1318.
11. Sardanelli F, Boetes C, Borisch B, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010;46:1296-1316.
12. Ikeda DM, Hylton NM, Kuhl CK, et al. BI-RADS: magnetic resonance imaging, 1st edition. In: D'Orsi CJ, Mendelson EB, Ikeda DM, et al, eds. Breast Imaging Reporting and Data System: ACR BI-RADSVBreast Imaging Atlas. Reston, VA: American College of Radiology; 2003.
13. Baltzer PA, Dietzel M, Kaiser WA. Nonmass lesions in magnetic resonance imaging of the breast: additional T2-weighted images improve diagnostic accuracy. J Comput Assist Tomogr. 2011;35:361-366.
14. Dietzel M, Baltzer PA, Vag T, et al. The necrosis sign in magnetic resonancemammography: diagnostic accuracy in 1,084 histologically verified breast lesions. Breast J. 2010;16:603-608.
15. Sinha S, Lucas-Quesada FA, Sinha U, et al. In vivo diffusion-weighted MRI of the breast: potential for lesion characterization. J Magn Reson Imaging. 2002;15:693-704. (Pubitemid 34606504)
16. Guo Y, Cai YQ, Cai ZL, et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging. 2002;16:172-178. (Pubitemid 34810055)
17. Ei Khouli RH, Jacobs MA, Mezban SD, et al. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology. 2010;256:64-73.
18. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89. (Pubitemid 46535708)
19. Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010;28:1450-1457.
20. Kuhl CK, Schrading S, Strobel K, et al. Accelerated breast MRI for breast cancer screening. ASCO. J Clin Oncol. 2013;31(suppl 26; abstr 1):2013.
21. Schrading S, Kuhl CK. Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology. 2008;246:58-70. (Pubitemid 350305027)
22. Kriege M, Brekelmans CT, Peterse H, et al. Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat. 2007;102:357-363. (Pubitemid 46474846)
23. Schnall MD, Blume J, Bluemke DA, et al. Diagnostic architectural and dynamic features at breast MR imaging: multicenter study. Radiology. 2006;238:42-53. (Pubitemid 43010579)
24. Gutierrez RL, DeMartini WB, Eby PR, et al. BI-RADS lesion characteristics predict likelihood of malignancy in breast MRI for masses but not for nonmasslike enhancement. AJR Am J Roentgenol. 2009;193:994-1000.
25. Cprum CA, Babcock A, Idiyatullin D, et al. The utility of sweep imaging with Fourier transform (SWIFT) in breast cancer. Proc Intl Soc Mag Reson Med. 2012;20:457.
26. Herrmann KH, Baltzer PA, Dietzel M, et al. Resolving arterial phase and temporal enhancement characteristics in DCE MRM at high spatial resolution with TWIST acquisition. J Magn Reson Imaging. 2011;34:973-982.
27. Mann RM, Mus RD, Geppert C, et al. Ultrafast dynamic imaging of the breast at diagnostic spatial resolution using TWIST. Proc Intl Soc Mag Reson Med. 2011;19:1016.
28. Pickles MD, Gibbs P, Bayram E, et al. TRICKS based DCE-MRI: a potential route to both high spatial and high temporal resolution breast dynamic datasets. Proc Intl Soc Mag Reson Med. 2012;20:1482.
29. Saranathan M, Rettmann DW, Hargreaves BA, et al. High spatio-temporal resolution breast dynamic contrast enhanced MRI at 3 T. Proc Intl Soc Mag Reson Med. 2012;20:456.
30. Le Y, Kipfer H, Majidi S, et al. Application of time-resolved angiography with stochastic trajectories (TWIST)-Dixon in dynamic contrast-enhanced (DCE) breast MRI. J Magn Reson Imaging. 2013;38:1033-1042.
31. Veltman J, Stoutjesdijk M, Mann R, et al. Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions. Eur Radiol. 2008;18:1123-1133.
32. Pinker K, Grabner G, Bogner W, et al. A combined high temporal and high spatial resolution 3 tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol. 2009;44:553-558.
33. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
34. Platel B, Mus R, Welte T, et al. Automated characterization of breast lesions imaged with an ultrafast DCE-MR protocol. IEEE Trans Med Imaging. 2013. [Epub ahead of print].
35. Moore SG, Shenoy PJ, Fanucchi L, et al. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population. BMC Health Serv Res. 2009;9:9.
36. Taneja C, Edelsberg J, Weycker D, et al. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol. 2009;6:171-179.
37. Thorpe S, Salkovskis PM, Dittner A. Claustrophobia in MRI: the role of cognitions. Magn Reson Imaging. 2008;26:1081-1088.
38. Berg WA, Blume JD, Adams AM, et al. Reasons women at elevated risk of breast cancer refuse breast MR imaging screening: ACRIN 6666. Radiology. 2010;254:79-87.
39. Niendorf HP, Dinger JC, Haustein J, et al. Tolerance data of Gd-DTPA: a review. Eur J Radiol. 1991;13:15-20.
40. Thomsen HS, Morcos SK, Almen T, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol. 2013;23:307-318.
41. Delille JP, Slanetz PJ, Yeh ED, et al. Physiologic changes in breast magnetic resonance imaging during the menstrual cycle: perfusion imaging, signal enhancement, and influence of the T1 relaxation time of breast tissue. Breast J. 2005;11:236-241. (Pubitemid 41026036)
42. Kuhl CK, Bieling HB, Gieseke J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology. 1997;203:137-144. (Pubitemid 27142721)
43. Schnur JB, Montgomery GH, Hallquist MN, et al. Anticipatory psychological distress in women scheduled for diagnostic and curative breast cancer surgery. Int J Behav Med. 2008;15:21-28. (Pubitemid 351451089)
44. Brett J, Bankhead C, Henderson B, et al. The psychological impact of mammographic screening: a systematic review. Psychooncology. 2005;14:917-938. (Pubitemid 41701209)
45. Pediconi F, Miglio E, Telesca M, et al. Effect of preoperative breast magnetic resonance imaging on surgical decision making and cancer recurrence rates. Invest Radiol. 2012;47:128-135.
46. Taylor JS, Reddick WE. Evolution from empirical dynamic contrast-enhanced magnetic resonance imaging to pharmacokinetic MRI. Adv Drug Deliv Rev. 2000;41:91-110. (Pubitemid 30122951)
47. Tofts PS, Berkowitz B, SchnallMD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med. 1995;33:564-568.
48. Gibbs P, Liney GP, Lowry M, et al. Differentiation of benign and malignant sub-1 cm breast lesions using dynamic contrast enhanced MRI. Breast. 2004;13: 115-121. (Pubitemid 38443607)
49. Hoffmann U, Brix G, Knopp MV, et al. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med. 1995;33:506-514.
50. Huang W, Tudorica LA, Li X, et al. Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging. Radiology. 2011;261:394-403.
51. Renz DM, Diekmann F, Schmitzberger FF, et al. Pharmacokinetic approach for dynamic breast MRI to indicate signal intensity time curves of benign and malignant lesions by using the tumor flow residence time. Invest Radiol. 2013;48:69-78.
52. Port RE, Knopp MV, Brix G. Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med. 2001;45: 1030-1038.
53. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology. 1994;193:777-781.
54. Tudorica LA, Oh KY, Roy N, et al. A feasible high spatiotemporal resolution breast DCE-MRI protocol for clinical settings. Magn Reson Imaging. 2012;30: 1257-1267.
55. Le Y, Kroeker R, Kipfer HD, et al. Development and evaluation of TWIST Dixon for dynamic contrast-enhanced (DCE) MRI with improved acquisition efficiency and fat suppression. J Magn Reson Imaging. 2012;36:483-491.
56. Dromain C, Boyer B, Ferre R, et al. Computed-aided diagnosis (CAD) in the detection of breast cancer. Eur J Radiol. 2013;82:417-423.
57. Mann RM, Veltman J, Huisman H, et al. Comparison of enhancement characteristics between invasive lobular carcinoma and invasive ductal carcinoma. J Magn Reson Imaging. 2011;34:293-300.
58. Rosen EL, Smith-Foley SA, DeMartini WB, et al. BI-RADS MRI enhancement characteristics of ductal carcinoma in situ. Breast J. 2007;13:545-550. (Pubitemid 350045709)